Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Cancer link to blood pressure drugs

  • Comment

A “modest” increase in the risk of cancer has been linked to a set of drugs that treat heart failure and high blood pressure.

The finding by US researchers has led some doctors to tell patients to stop taking the drugs, which are potential life savers.

Researchers found only a small chance of someone developing cancer while taking angiotensin receptor blockers (ARB) but the findings have been branded “disturbing and provocative” by one expert.

Although the drugs are considered safe, one previous trial reported a significant increase in fatal cancers in patients treated with the ARB candesartan.

To carry out the new investigation, US researchers pooled together and analysed all the previously published data from ARB studies before November 2009.

They also looked at new data from five trials involving 61,590 patients, and trends relating to lung, prostate and breast cancers, and cancer deaths. Part of the analysis involved deaths among 93,515 patients who took part in eight trials.

More than 85% of the patients were taking one type of ARB, telmisartan.

The findings showed that 7.2% of patients taking ARBs were diagnosed with a new cancer over a period of four years compared with 6% of patients not treated with the drugs.

Although the result was significant, the authors led by Dr Ilke Sipahi, from Case Western Reserve University School of Medicine in Cleveland, Ohio, stressed that it should be seen in context.

“The finding of a 1.2% increase in absolute cancer risk over an average of four years needs to be interpreted in view of the estimated 41% background lifetime cancer risk,” they wrote in The Lancet Oncology medical journal.

Click here to see the Lancet article

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs